![]() |
|
|
Vol. 303, Issue 1, 11-16, October 2002
Department of Radiology, The University of Texas Health Science
Center at San Antonio, San Antonio, Texas
A novel method for prolonging the retention of liposomes in the
peritoneum while increasing liposome deposition in lymph nodes that
drain the peritoneum is described. An aliquot (1 ml) of technetium-99m (99mTc)-biotin-liposomes encapsulating blue dye was
injected intraperitoneally in rats. Thirty minutes after administration
of the 99mTc-blue-biotin-liposomes, five rats
(experimental) were administered avidin (5 mg) intraperitoneally,
whereas the remaining five rats served as controls. Scintigraphic
images were acquired at baseline and 1 and 24 h after the liposome
injection followed by a tissue biodistribution study. Images at 24 h clearly demonstrated very different distributions between the
experimental and control animals. In experimental rats, most of the
activity was visualized in the abdominal region, and in abdominal and
mediastinal lymph nodes. The percentage of the injected dose (% ID) in
the blood was significantly higher in the control group than in the
experimental group (14.0 ± 1.7 versus 0.17 ± 0.03%;
P < 0.001). The % ID in the spleen was also
significantly greater for controls (23.3 ± 3.9%) compared with
the experimental group (0.78 ± 0.8%; P = 0.001). Significant 99mTc activity was detected in
blue-stained abdominal nodes (4.7%) and mediastinal nodes (2.3%) from
the experimental animals, whereas no blue-stained nodes were detectable
in the control animals. The intraperitoneal biotin-liposome/avidin
delivery system described in this study could potentially be used for
delivery of liposome-encapsulated drugs to disease processes that
become disseminated in the peritoneum such as metastatic ovarian,
gastric, and colorectal cancer, as well as infectious peritonitis.
This article has been cited by other articles:
![]() |
J. S. Abramowicz Ultrasonographic Contrast Media: Has the Time Come in Obstetrics and Gynecology? J. Ultrasound Med., April 1, 2005; 24(4): 517 - 531. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Jensen, T. L. Andresen, J. Davidsen, P. Hoyrup, S. D. Shnyder, M. C. Bibby, J. H. Gill, and K. Jorgensen Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids Mol. Cancer Ther., November 1, 2004; 3(11): 1451 - 1458. [Abstract] [Full Text] [PDF] |
||||